Compare ARMOUR Residential REIT, Inc. (ARR) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Charles River Laboratories Intl. Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.7 (market cap $2.07B), while Charles River Laboratories Intl. Inc trades at $287.99 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 6.5× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| ARR | CRL | |
|---|---|---|
Market Cap | $2.07B | $13.46B |
Sector | Financials | Health |
52-Week High | $19.12 | $282.00 |
52-Week Low | $14.05 | $145.57 |
Dividend Yield | 17.28% | — |
Enterprise Value | — | $16.30B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
